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Abstract
A serine protease inhibitor from Enterolobium contortisiliquum (EcTI) belongs to the Kunitz family of plant inhibitors,
common in plant seeds. It was shown that EcTI inhibits the invasion of gastric cancer cells through alterations in integrin-
dependent cell signaling pathway. We determined high-resolution crystal structures of free EcTI (at 1.75 A˚) and complexed
with bovine trypsin (at 2 A˚). High quality of the resulting electron density maps and the redundancy of structural
information indicated that the sequence of the crystallized isoform contained 176 residues and differed from the one
published previously. The structure of the complex confirmed the standard inhibitory mechanism in which the reactive loop
of the inhibitor is docked into trypsin active site with the side chains of Arg64 and Ile65 occupying the S1 and S19 pockets,
respectively. The overall conformation of the reactive loop undergoes only minor adjustments upon binding to trypsin.
Larger deviations are seen in the vicinity of Arg64, driven by the needs to satisfy specificity requirements. A comparison of
the EcTI-trypsin complex with the complexes of related Kunitz inhibitors has shown that rigid body rotation of the inhibitors
by as much as 15u is required for accurate juxtaposition of the reactive loop with the active site while preserving its
conformation. Modeling of the putative complexes of EcTI with several serine proteases and a comparison with equivalent
models for other Kunitz inhibitors elucidated the structural basis for the fine differences in their specificity, providing tools
that might allow modification of their potency towards the individual enzymes.
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Introduction
Members of the superfamily characterized by the b-trefoil fold
[1] are structurally similar although their biological functions may
be widely different [2]. Such functions may include chlorophyll
binding [3], taste modification (miraculin [4]), binding to cytokine
receptors (IL-1b [5]), tight binding to ribosomes (ricin [6]) or
carbohydrate binding, exemplified by the Clitocybe nebularis lectin,
CNL [7]. Prominent among them are plant protease inhibitors of
the Kunitz type, the first one isolated by Kunitz [8] from soybeans
and named soybean trypsin inhibitor (STI). A complex of STI with
trypsin provided the first example of the interactions between a
member of this family and its target enzyme [9,10]. STI and
related proteins mainly inhibit serine proteases, although some
also inhibit cysteine and aspartic proteases [11]. Plant Kunitz
inhibitors are characterized by molecular mass of about
20,000 Da (for the whole protein or a domain), low content of
cysteine residues, and the presence of one or two reactive sites that
are responsible for their inhibitory activity. They are frequently
present in several polymorphic variants, exemplified by the STI
isoforms, Tia and Tib, which differ by nine amino acids [12].
A Kunitz-type inhibitor that was first isolated from Enterolobium
contortisiliquum was named EcTI [13]. It was shown that EcTI
inhibits trypsin, chymotrypsin, plasma kallikrein, plasmin, human
neutrophil elastase, and Factor XIIa in the stoichiometric ratio
1:1, but not thrombin, bovine pancreatic elastase, or Factor Xa
[13,14]. The primary structure of EcTI was determined by
automated Edman sequencing [15] after digestion of the protein
with trypsin, chymotrypsin, and protease from S. aureus. A
molecule of EcTI was shown to contain two polypeptide chains
consisting of 134 and 40 amino acid residues each, covalently
bound through a disulfide bond, with one residue (116)
unidentified [13]. The protein was subsequently crystallized and
a 2 A˚ data set was collected [16], but full structure determination
was not completed.
An investigation of the biological properties of EcTI has
concluded that this inhibitor showed no effect on the proliferation
of gastric cancer cells or fibroblasts but inhibited the adhesion,
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migration, and cell invasion of gastric cancer cells, with no effect
on the adhesion of fibroblasts. EcTI was shown to decrease the
expression and disrupt the cellular organization of molecules
involved in the formation and maturation of invadopodia. Gastric
cancer cells treated with EcTI exhibited a significant decrease in
intracellular phosphorylated Src and focal adhesion kinase,
integrin-dependent cell signaling components. It was speculated
that the mode of such activity of EcTI involves inhibition of the
invasion of gastric cancer cells through alterations in integrin-
dependent cell signaling pathways [14,17].
In this work, we investigated the structural basis of the activity of
EcTI by determining its crystal structure in the unbound and
trypsin-bound form. Modeling of the mode of binding of EcTI to
other serine proteases was used in order to elucidate the ability or
lack thereof to inhibit their activity.
Results and Discussion
Crystal Structures of EcTI
The plant protease inhibitor EcTI from Enterobobium contortisi-
liquum is a classical trypsin inhibitor belonging to the Kunitz
family. It exhibits potent inhibition of bovine pancreatic trypsin
and a number of other serine proteases (Table 1), but does not
inhibit several related enzymes, such as Factor Xa. In this study we
evaluated the ternary structure of the inhibitor and its interactions
with serine protease trypsin. Formation of the EcTI-trypsin
complex was tested on an analytical scale using a small column
BioSep-SEC-S 3000 (Phenomenex), indicating strong binding of
EcTI to bovine trypsin. A larger amount of the EcTI-trypsin
complex was prepared with a Sephacryl S-100 HR column. A
reasonably large single peak corresponding to EcTI-trypsin
complex was observed (Fig. 1). The complex was subsequently
crystallized and the crystal structure was determined at 2.0 A˚
resolution. The final model contains a single complex in the
asymmetric unit. The electron density for the trypsin molecule is
complete and all 223 amino acid residues are traced in the final
model (for consistency with the previous studies we used standard
chymotrypsin numbering, 16–245). In the EcTI molecule residues
belonging to the loop region 111–113, the C terminus of the
longer polypeptide chain (135–136), the N terminus of the shorter
chain (137–140), and the C terminus of the shorter chain (175–
176) were not included in the final model due to the lack of
electron density.
The structure of free EcTI was refined to a higher resolution of
1.75 A˚. The final model contains two inhibitor molecules, two
imidazole molecules, two glycerol molecules, and 244 water
molecules. Molecule A consists of residues 1–134 and 141–174,
whereas molecule B contains residues 1–134 and 141–173. A loop
region containing residues 23–26 of monomer B is in weak
electron density, but is still included in the final model, whereas the
density for the loop containing residues 111–113, not traced in the
complex, is very clear.
Both structures were validated with the program MolProbity [18]
which showed over 95% residues falling within the favored area
and no residues in the disallowed regions, indicating acceptable
quality of the structures.
Redetermination of the Sequence of EcTI
Strikingly, the high resolution structure of free EcTI indicated
that the crystallized protein is a new isoform, since its sequence
differs in a number of places from the one reported previously
Figure 1. Preparation of the EcTI-trypsin complex. Free EcTI and its complex with trypsin were run on the same Sephacryl S-100 HR column,
with the same buffer. The two curves were overlaid, with the blue one representing EcTI-trypsin and the red one representing free EcTI.
doi:10.1371/journal.pone.0062252.g001
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(Accession ID P86451 [13]). The measured molecular mass of the
disulfide-linked EcTI molecule, obtained with an electrospray
mass spectrometer, was 19851.5 Da, whereas the mass calculated
from the previously published sequence was only 19475.2 Da.
After reduction of the disulfide bonds the molecular mass of the C-
terminal chain was 4440.2 Da, lower than the isotopically
averaged calculated 4482.9 Da. The latter discrepancy was
resolved by replacing Arg154 with a leucine, very clearly
delineated in the electron density map in both molecules. This
replacement changed the calculated mass of this chain to 4439.9,
in excellent agreement with the experimentally determined value.
A larger number of changes were required to determine the
sequence of the N-terminal chain. Two residues (Gln102 and
Glu111) had to be inserted, and the identity of 17 residues
changed. The isotopically averaged mass of the fully reduced N-
terminal chain of EcTI is now calculated as 15416.5, compared to
the experimentally determined 15418.5. The sequence of this
isoform of EcTI and its comparison with the sequences of other
Kunitz inhibitors is shown in Fig. 2.
Description of the Three-dimensional Structure of EcTI
The fold of EcTI is a b-trefoil, typical for the STI-related family
of Kunitz inhibitors. Such a fold contains twelve b-strands (labeled
b1 to b12) arranged into three structurally similar units related by
pseudo-threefold symmetry (Fig. 3a). A b-barrel which creates a
significant hydrophobic core is formed by all twelve b-strands.
Loop L10 is present only nominally, since this part of the structure
includes the C terminus of the longer chain and the N terminus of
the shorter chain, both partially disordered. The reactive loop (L5)
responsible for the inhibitory properties is located between b-
strands 4 and 5. Since the crystals of free EcTI contain two
molecules in the asymmetric unit, it is possible to evaluate the
influence of crystal packing on its structure. The root-mean-square
deviation (RMSD) between the coordinates of the two molecules is
0.36 A˚, calculated for 150 pairs of superimposed Ca atoms. A
significant difference was observed at the loop L8 between b-
strands 7 and 8, most likely caused by the interactions between two
molecules, since the L8 loops of both of them are involved in
forming dimer contacts. Other contact areas include loops L5
(reactive loop), L10, and L11 of molecule A, and loop L1, strand
b1, reactive loop L5, and the loop L6 of molecule B (Fig. 3b).
However, since the protein migrates on gels as a monomer (Fig. 1),
the observed dimer is a crystallization artifact.
Only a single EcTI-trypsin complex is present in the asymmetric
unit of its crystals. EcTI binds to the active site of trypsin through
its reactive loop (Fig. 3c). The molecules of EcTI in the complex
are very similar to their counterparts in the unbound EcTI
structure. The RMSDs between the complexed EcTI and
molecules A and B of the free inhibitor are 0.305 and 0.245 A˚,
respectively. The most significant difference between the free and
complexed EcTI is the conformation of the loop L8 (residues 107–
117). Residues 110–113 are disordered in the complex while well
ordered in both molecules of the free inhibitor. However, in the
latter two structures the conformation of loop L8 is significantly
different. In molecule B the conformation of this loop is closer to
the one observed in the complex structure, whereas in molecule A
its conformation is very different, most likely due to crystal
contacts. In the structure of the complex residues 114–116 of the
inhibitor are significantly shifted (as much as 4.3 A˚ for Ca of
Leu115), compared to their position in the structure of free
inhibitor in molecule B. This shift is most likely driven by multiple
interactions with residues 97–99 of trypsin and by hydrophobic
interactions with the side chain of Trp215.
Similarly to the situation observed in the STI-porcine trypsin
complex [10], formation of the EcTI-trypsin complex does not
lead to significant overall conformational changes of the reactive
loop. Structural differences are primarily limited to the main chain
in the vicinity of the P1 residue Arg64 which occupies the S1
pocket of trypsin. As a result, the orientation of the side chain of
Arg64 has changed upon binding allowing a perfect fit of this
residue in the S1 pocket (Fig. 4a). However, we have not observed
the lowering of the B-factors of the reactive loop residues upon
enzyme binding, reported for other similar complexes [10,19]. A
comparison of the trypsin component of the complex with the
structure of the inactivated enzyme containing monoisopropyl-
phoshoserine instead of the catalytic Ser195 (PDB ID: 5PTP)
indicates the absence of any significant conformational changes in
the enzyme that could be traced to binding of EcTI (RMSD
0.50 A˚ for a superposition of all 223 Ca atoms).
A molecule of EcTI contains two disulfide bonds, one intra-
chain and one connecting two chains. The intra-chain bond
involves Cys40 and Cys86, connecting loops L3 and L6, and an
equivalent disulfide bond is observed in most Kunitz-type
inhibitors [20]. The second disulfide bond is formed by Cys133
and Cys142, covalently connecting the two polypeptide chains,
thus providing additional stability to the b-trefoil. That bond is
also conserved in most other Kunitz inhibitors, although it is
usually intra-chain rather than inter-chain. However, since the
crystal structures of EcTI were obtained under mildly reducing
buffer conditions, the disulfide bond Cys40-Cys86 was broken in
molecule A of the free EcTI, as well as in the inhibitor molecule in
the EcTI-trypsin complex. This observation indicates that the
disulfide bond Cys133-Cys142 plays a more important role in
stabilizing the b-trefoil fold, whereas the disulfide bond Cys40-
Cys86 may not be as necessary for its stability.
Table 1. Inhibitory properties of EcTI and the related
inhibitors.
EcTI STI TKI*
Bovine trypsin Ki (nM) 0.88 (60.25) 1.29 (60.73) 3.2
Bovine chymotrypsin
Ki (nM)
1.11 (60.67) 70.29 (631.67)
Human plasma
kallikrein Ki (nM)
6.15 (60.98) 5.70 (63.54)
Human plasmin
Ki (nM)
9.36 (60.92) 192.10 (678.37)
Human factor Xa
Ki (nM)
n.i. 1367.59 (6218.20) 220
Human factor XIIa
Ki (nM)
81.81 (614.89) n.i.
Human plasminogen
Ki (nM)
n.i. n.i.
Porcine pancreatic
kallikrein
n.i.
Bovine pancreatic
elastase
n.i.
Human neutrophil
elastase Ki (nM)
55
n.i – no inhibition. The values in parentheses correspond to the standard
deviations of the calculated data. Blank fields – data not collected or available.
*Taken from Patil et al. [19].
doi:10.1371/journal.pone.0062252.t001
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Structural Comparison of EcTI with Other Inhibitors
A sequence alignment of EcTI and its selected homologues is
shown in Fig. 2. The alignment utilized three-dimensional
structures of the proteins if known, otherwise only their primary
structures. EcTI shows the highest sequence identity of 87% with a
trypsin inhibitor from Acacia confusa. The sequence identity
between EcTI and DE5, a trypsin inhibitor from Adenanthera
pavonina, is 67%, and the identities between EcTI and Bauhinia
variegata trypsin inhibitor, ETI, WCI, TKI, and STI are 45%,
38%, 34%, 44%, and 40%, respectively. However, crystal
structures are not available for the most closely related evolution-
ary counterparts of EcTI, trypsin inhibitors from Acacia confusa and
Adenanthera pavonina. Not surprisingly, the sequence alignment
shows that the most highly conserved residues are located in the b-
strand regions, being responsible for creation of the common b-
trefoil fold. On the other hand, the presence of residues that are
not conserved allows these STI family members to exhibit different
biological functions.
Other Kunitz-type inhibitors with experimentally determined
structures that share the b-trefoil fold with EcTI are STI, TKI,
ETI, and WCI. When the structure of EcTI was superimposed
with STI and TKI, the b-trefoil portions were overlaid fairly well,
with the respective RMSD values of 0.44 A˚ for the 101 pairs of
superimposed Ca atoms of STI and 0.49 A˚ for 99 atom pairs of
TKI. However, significant differences are found at the loop
regions. For example, the tracing of loops L6 and L8 is completely
different in EcTI and STI, with the largest distance between the
L6 loops being as much as 14.6 A˚ (Fig. 4b). However, the
differences in the reactive loops of these two proteins are relatively
minor, with the loops L5 retaining very similar shape and the
largest deviation not exceeding 1.5 A˚ (see below).
The Reactive Site
As found in most known Kunitz-type inhibitors [2], EcTI has a
single reactive site located on loop L5, between b-strands 4 and 5.
An exception is the recently published complex structure of a
double-headed serine arrowhead protease inhibitor, API-A com-
plexed with two molecules of trypsin, in which two reactive sites
are located in loops L6 and L10 [21]. However, the latter protease
inhibitor may represent a different evolutionary pathway. The
electron density maps for the reactive loops of both the free EcTI
(Fig. 5a) and in a complex with trypsin (Fig. 5b) are well defined,
indicating the presence of stable conformations. We did not
observe lowering of the B-factors of the backbone of the reactive
loop upon complex formation, unlike what was reported for STI
and TKI [10,19]. This difference is very likely due to the
involvement of the reactive loops of both EcTI molecules located
in an asymmetric unit of the crystals of free inhibitor in dimer
formation. However, the B-factor of the side chain of Arg64, the
P1 residue of the inhibitor, is significantly lower in the complex
than in the free inhibitors, due to numerous interactions of its
extended side chain with the residues comprising the tight S1
pocket in the active site of trypsin. These interactions include a
strong ion pair with Asp189, located at the bottom of the pocket.
The side chains of Arg64 are exposed to the solvent in both EcTI
molecules present in an asymmetric unit of the crystals of the free
inhibitor.
As discussed above, despite the extensive structural conservation
of the overall b-trefoil folds of Kunitz-type inhibitors and excellent
Figure 2. Sequence alignment of EcTI and related serine protease inhibitors, partially structure-based (the structures of Acacia,
DE5, and Bauhinia (rows 2–4) have not been determined). The top two sets of rows correspond to the long chain in EcTI, and the third set of
rows represents the short chain. The secondary structure elements of EcTI are shown on top of the alignment in orange. Residues identical in all
inhibitors are colored green and those identical in some, red. The reactive loop regions are highlighted in yellow, and a blue triangle indicates the
position of P1 residue.
doi:10.1371/journal.pone.0062252.g002
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Figure 3. EcTI and its complex with trypsin. (a) Ribbon representation of the overall three-dimensional structure of EcTI. b-strands labeled b1–12
are shown in red, and loops labeled L1–13 are in green. Loop L10 is only marked for consistency with the other related structures, since the main
chain is broken in this region. (b) Pseudo-dimer of the two crystallographically independent molecules of EcTI in the asymmetric unit. The main
contact loops are labeled. (c) Overall structure of the EcTI-trypsin complex shown as a cartoon diagram. EcTI is colored green, while trypsin is red, and
the reactive loop is labeled.
doi:10.1371/journal.pone.0062252.g003
Figure 4. Superposition of EcTI in free and bound state. (a) Interface between EcTI (yellow ribbon) and trypsin (green space filling
representation) in the inhibitor-trypsin complex. The side chains of Arg64 and Leu115 of EcTI are shown as sticks. A superimposed tracing of molecule
B of free EcTI is shown in red, clearly indicating that the conformational changes in the reactive loop around Arg64 are needed in order to avoid
clashes and allow the proper fit of its side chain into the S1 pocket of the enzyme. (b) Steroview of the superposition of trypsin-bound EcTI and STI
(PDB ID: 1AVW). Color highlights are for the loops which are most different between these two proteins, blue for EcTI and red for STI, whereas other
parts of the chain are gray.
doi:10.1371/journal.pone.0062252.g004
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superposition of their b strands, conformations of some loops are
quite different. However, conformations of the reactive loops L5
are very similar, although their amino acid sequences are not
highly conserved. A network of hydrogen bonds formed by the
side chain of Asn13 (STI numbering) with the reactive loop
residues was thought to play an important role in stabilizing the
conformation of the reactive loop [10]. The equivalent residue in
EcTI is also Asn13, which similarly forms a network consisting of
several hydrogen bonds. In addition, seven hydrogen bond
interactions (Ala66-O-Asn13-N, Leu68-N-Leu11-O, Leu68-O-
Figure 5. The reactive loop of EcTI. (a,b) 2Fo-Fc electron density maps contoured at 1.2s of the reactive loop area of (a) free EcTI and (b) its
complex with trypsin. (c) A steroview of the hydrogen networks of the reactive loop region of a molecule of free EcTI. Blue dashed lines indicate the
hydrogen bond network formed by the side chain of Asn13 and the interacting residues, and red dashed lines indicate the hydrogen bond network
formed by the reactive loop region residues and their partners. Green spheres represent water molecules.
doi:10.1371/journal.pone.0062252.g005
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H2O-Leu3-N, Thr69-O-Ala71-N, Thr69-O-Phe72-N, Thr69-O-
H2O-Ile121-N, and Phe72-O-H2O-Ile121-N) might play an
essential role in stabilizing the conformation of the reactive loop
(Fig. 5c). These hydrogen bonds involve residues extending from
P29 to P89 and their immediate environment.
Superposition of the structures of the complexed and free EcTI
reveals that there is no significant conformational change of the
reactive loop upon binding to trypsin. Taking monomer B of free
EcTI as a reference, only the Ca atoms of the P1, P2, and P19
residues exhibit minor shifts, whereas the remaining residues of the
reactive loop are in almost exactly the same conformation. Among
these three residues, the largest movement (1.5 A˚) involves the P1
residue (Fig. 4a). The conformational changes can be further
elucidated by the changes in the dihedral angles. The P1, P2, and
P19 residues of free EcTI monomer B have dihedral angels (Q/y)
of 280.6/75.4, 260.2/156.1, and 2133.6/140.0, respectively,
whereas the equivalent residues in the complex have dihedral
angles of 293.0/40.9, 264.7/142.6, and 276.8/156.0, respec-
tively. The largest changes are for the dihedral angle y of the P1
residue and Q of the residue at P19. However, this minor
conformational change is indispensable for complexation. Fig. 4a
shows the potential clashes between the reactive loop of free EcTI
and trypsin.
Whereas the reactive loops of EcTI, STI, and TKI bound to
trypsin adopt almost identical conformations when the trypsin
components of the complexes are superimposed, the inhibitors
themselves are not well superimposed despite their high structural
similarity (Fig. 6a). If the inhibitor components of the complex are
superimposed instead, we observe very accurate overall superpo-
sition of their b sheets, whereas the reactive loops are not well
superimposed (Fig. 6b). Thus in a superposition in which both
components, trypsin and the inhibitors, were to be individually
and optimally superimposed using the STI complex as a guide, the
reactive site of EcTI would be misaligned in relation to the active
site of trypsin. In particular, the side chain of Arg64 would clash
with the wall of the active site of trypsin, instead of occupying the
proper S1 binding pocket. However, when the actual orientation
of EcTI bound to trypsin is considered, the superposition of the
reactive loops as well as of the side chains of Arg64 is excellent
(Fig. 6c). Therefore, the only way to avoid such clashes while
preserving conserved conformation of the reactive loop (as
observed in various Kunitz inhibitor complexes with trypsin) is
through a rigid body movement of the inhibitor molecule
(Fig. 6a,c). The inhibitor molecules are rotated by ,10u relative
to each other in the EcTI and STI complexes with trypsin, a value
similar to the rotation of eglin-C in its complexes with subtilisin
and thermitase [22].
Interface between the Enzyme and the Inhibitor
EcTI belongs to the family of substrate-like inhibitors charac-
terized by the presence of a reactive site loop in canonical
conformation [10]. Its reactive site adopts a classical noncovalent
‘‘lock and key’’ inhibitory mechanism. The side chain of the P1
residue Arg64 acts exactly like a key inserting into the active site of
trypsin. The whole contact area is 987 A˚2 as calculated with the
program PISA [23]. The interaction pattern between EcTI and
trypsin is shown in Fig. 7a and is summarized in Table 2. Eight
EcTI residues make hydrogen bonds to trypsin, and eleven
residues in EcTI are involved in hydrophobic interactions with
trypsin. Not surprisingly, a majority of these residues are located in
the reactive loop. Additional interactions are provided by the
surrounding residues from the N terminus, as well as loops L6 and
L8. The key P1 residue, Arg64, interacts with seven residues of
trypsin. The NH2 atom of the guanidinium group of Arg64 makes
an ionic interaction with the carboxylate group OD2 of trypsin
Asp189 at a distance of 2.99 A˚, and also makes a hydrogen bond
with the carbonyl O atom of trypsin Gly219. The carbonyl O
atom of Arg64 accepts two hydrogen bonds from the main chain
amide nitrogens of Gly193 and Ser195 in trypsin, whereas the
main-chain amide of Arg64 is engaged in forming hydrogen bonds
with the carbonyl oxygens of trypsin Ser195 and Ser214. The
NH1 group interacts with the hydroxyl group OG of trypsin
Ser190. In addition, the nitrogen NE atom makes indirect
hydrogen bonds with the carbonyl oxygens of three trypsin
residues, Gly216, Gly219 and EcTI Pro62, mediated by a water
molecule. In total, Arg64 forms a salt bridge with Asp189 of
trypsin, as well as six direct hydrogen bonds and three indirect
hydrogen bonds. In the reactive loop region, other contributing
residues include Thr61 (P4), Pro62 (P3) and Ala66 (P29), which
form hydrogen bonds with several residues in trypsin. At the N-
terminus of EcTI, residues Arg12, Asn13, and Gly14 are involved
in water-mediated interactions with residues in trypsin. The NH1
atom of Arg92, a residue residing in the L6 loop, forms a hydrogen
bond with the carbonyl OE1 of Gln221 in trypsin. Apart from
these polar residues, eleven residues in EcTI contribute to
hydrophobic interactions with trypsin. They are Ile10, Gly15,
and Thr16 from the N terminus, Ile58, Trp60, Pro63, Ile65 and
Ile67 from the reactive loop, and Ser114, Leu115, and Phe116
from loop L8. For the trypsin component, contact area mainly
comprises the S1 pocket, occupied by the side chain of P1 residue
Arg64 (Fig. 7b), and the surrounding area. The presence of two
consecutive proline residues in the reactive loop of EcTI makes the
sequence of this loop unique among other Kunitz inhibitors, but
does not change the canonical binding mode.
Structural Basis of Inhibitory Activities
Crystal structure of the EcTI-trypsin complex reveals the
binding mode of this inhibitor to trypsin, demonstrating the
conserved conformation of the reactive loop of the inhibitor
docked in the active site of the enzyme. The side chain of the P1
residue, Arg64, is involved in charge-charge interactions with
Asp189 in the S1 pocket of trypsin. That highly conserved
interaction defines the primary specificity for the recognition of the
trypsin-like serine proteases by Kunitz type inhibitors. A compar-
ative analysis of the interactions reported here with those observed
in the complexes of the other enzymes with similar inhibitors may
provide a structural insight into the specificity and the potency of
the inhibitors towards the individual enzymes.
EcTI is a potent inhibitor of several serine proteases including
trypsin, chymotrypsin, plasma kallikrein, and plasmin, and a
slightly less potent inhibitor of Factor XIIa (Table 1). However,
EcTI does not inhibit Factor Xa (FXa) and human plasminogen
(Table 1). Factor Xa is a serine protease involved in the
coagulation cascade and is a potential target for the development
of new antithrombotics. The structure of FXa is comprised of two
chains, with the heavy chain exhibiting 37% sequence identity
compared to bovine pancreatic trypsin. The RMSD between the
heavy chain of Factor Xa in its atomic-resolution structure (PDB
ID: 2JKH; [24]) and bovine trypsin (this work) is 0.65 A˚ for 169
Ca pairs, indicating very high conservation of their overall folds.
The S1 pockets of both enzymes contain the negatively-charged
Asp189, defining the primary specificity requirement of the
presence of either arginine or lysine residue in the P1 position in
the inhibitor. However, although Factor Xa is inhibited with low
micromolar Ki by STI (Table 1) and with 220 nM Ki by TKI, a
Kunitz type trypsin inhibitor from tamarind [19], it is not
inhibited by EcTI. Superposition of the structure of FXa (PDB
code 2JKH) on the trypsin molecule in the EcTI complex based on
Crystal Structure of EcTI
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the Ca atoms reveals three potential areas of conflict for the EcTI
binding to FXa. The first area includes the loop comprising
residues 78–95 in EcTI, which adopts significantly different
conformation than that in TKI and STI (Fig. 8a). As a result, a
fragment of this loop that contains Arg92 would be placed very
close to the loop 219–223 in FXa. The latter loop contains
Arg222, and these two positively charged residues would collide. A
trypsin residue that is structurally equivalent to Arg222 is Gln221,
involved in favorable interactions with EcTI by forming a
hydrogen bond with Arg92. Therefore, binding of EcTI to FXa
would lead to potential clashes and the loss of a favorable
interaction in this area when compared with binding of this
inhibitor to trypsin. On the other hand, binding of TKI and STI
to FXa would not lead to any negative effects in this area, due to
different conformations of the loop 78–95.
The second site is located at the interface between the loops 13–
15 in the inhibitors and 142–151 in the enzymes. In contrast to the
previously described site, the conformation of this loop in different
inhibitors is well preserved. This loop plays an important role
maintaining the conformation of the reactive loop in the structures
of all three inhibitors in the complexes with trypsin. Substitution of
Asn143 in trypsin by Arg in FXa creates a potential clash with the
main chain of the loop in the vicinity of Asn13. The latter residue
forms several hydrogen bonds with the backbone of the reactive
loop in the inhibitors. Any conformational changes in this area
which would be needed to find a compromise solution for the
inhibitor binding to FXa might affect the inhibition constant, and
indeed, the binding of STI and TKI to FXa is weaker than to
trypsin (Table 1).
The third site is the interface between the loops in the inhibitors
and the enzymes with different conformations in both counter-
parts. Loop 171–175, following the conserved helical turn 167–
171, has a different conformation in FXa then in trypsin. Loop
110–115 in EcTI and the corresponding fragments in STI and
TKI differ in their conformation and sequence. Although the
fragment 111–113 of this loop in EcTI is disordered, the
conformation of the loop for the residues 114–115 is sufficiently
similar between the bound and unbound state of the inhibitor to
provide confidence for using this fragment for modeling purposes.
Simple modeling shows clashes between the main chain of the
latter and the side chain of Phe174 of FXa (Fig. 8b). Interestingly,
the sequence of this fragment in TKI has only residues with small
side chains (Ser116, Ala117, Ala118), and does not have any steric
problems with accommodating a different conformation of the
loop 172–175 in FXa. However, STI has large Trp side chain at
the position 117, which may have potential clashes with the side
chain of Phe174 in FXa (Fig. 8b). This observation is in a good
agreement with the differences in the inhibition constants for STI
and TKI (Table 1) and may explain why STI is worse inhibitor of
FXa than TKI.
Significant differences in the inhibition constants for EcTI and
STI are seen towards chymotrypsin and plasmin (Table 1). EcTI
is between one and two order magnitude more potent towards
these enzymes than STI. Possible steric problems that could be
elucidated upon the simple modeling of STI and EcTI inhibitors
in the active sites of these two enzymes might be addressed to the
differences in the positions of their N termini. When the three
inhibitors are superimposed, the orientation of the N termini in
STI and TKI is similar, whereas the N terminus of EcTI is shifted
(Fig. 8c). These differences can be related to the presence of the
longer side chain of Leu3 and Ile10 in EcTI compared to shorter
valine and proline side chains, occupying structurally equivalent
positions in STI and TKI, respectively. These residues are
involved in numerous hydrophobic interactions within the
hydrophobic core comprising residues Leu11, Ile121 and
Phe169. Incorporation of the longer side chains of Leu3 and
Ile10 requires some adjustment in the orientation of the residues
for optimization of the hydrophobic interactions within the core,
resulting in the shift of the N termini in EcTI (Fig. 8c).
Figure 6. Rigid body movement of the Kunitz inhibitors bound to trypsin. (a) Superposition of the trypsin complexes with EcTI, STI, and TKI
based on the Ca coordinates of trypsin reveals overall rigid body shifts of the inhibitors. The tracing of the trypsin chain in the complex with EcTI is
shown as green ribbon, EcTI is yellow, STI red, and TKI magenta. (b) Superposition of EcTI, STI, and TKI based on their Ca coordinates (colored as in
panel (a)) reveals a small change in the orientation of the reactive loop (residues 61–67). (c) Superposition of EcTI bound to trypsin with the STI
complex. STI is shown in orange and trypsin in space-filling green. In order to show the reason for the rigid body movement of EcTI it is shown twice,
in yellow when superimposed directly on STI, and in blue when the trypsin molecules of the two complexes were superimposed.
doi:10.1371/journal.pone.0062252.g006
Figure 7. Close-up of the interactions of EcTI and trypsin. (a) Steroview of the region of interactions, with residues belonging to trypsin shown
as cyan sticks and the disulfide bond colored yellow. The residues of EcTI are shown as green sticks and the gray spheres represent water molecules.
Hydrogen bonds are indicated by red dashed lines. (b) Interface of the EcTI-trypsin complex, with EcTI shown as a green ribbon with selected side
chains in stick representation, whereas the surface of trypsin is colored according to charge (blue positive, red negative, gray uncharged).
doi:10.1371/journal.pone.0062252.g007
Crystal Structure of EcTI
PLOS ONE | www.plosone.org 10 April 2013 | Volume 8 | Issue 4 | e62252
The differences in the orientations of the N termini of the
inhibitors in the complexes are much more prominent due to the
rigid body movement of the inhibitors described above. In a model
of the complex of STI with chymotrypsin (PDB ID: 1YPH),
Phe566 of STI would collide with Phe39 in chymotrypsin, and the
changes in the orientation of its side chain are restricted by close
proximity of the side chain of Phe502 on the N terminus of STI.
The N terminus of EcTI is not close to the enzyme and instead of
bulky Phe566, this inhibitor has an isoleucine at this position.
The loop 605–613 in plasmin (PDB ID: 1BML; [25]),
equivalent to the loop 59–62 in trypsin, has a four-residue
insertion. Two of them, Glu606 and Lys607, would be involved in
clashes with the residues of STI in a modeled complex. In
particular, the side chain of Lys607 collides with the positively
charged N terminus of STI, whereas the N terminus of EcTI is
located ,8 A˚ away. In summary, these considerations could
explain why EcTI is a better inhibitor of chymotrypsin and
plasmin than STI (Table 1).
Whereas the modeling which was used in this study in an effort
to explain the biochemical data was very simple, the resulting ideas
of the structural basis for the differences in the potency of the
inhibitors could be tested further. It should be possible to either
increase the specificity of the individual inhibitors for a particular
enzyme, or to make an inhibitor more promiscuous and able to
efficiently inhibit a larger variety of targets.
Materials and Methods
Preparation and Purification of EcTI-trypsin Complex
Purification of the inhibitor EcTI by itself was carried out as
previously described [13,16]. For preparation of the complex,
equimolar amounts of EcTI and bovine pancreatic trypsin (Sigma)
were mixed and incubated overnight at room temperature in
20 mM Tris pH 8.0, 200 mM NaCl, 5% glycerol, and 6 mM b-
mercaptoethanol. The mixture was then applied onto a Sephacryl
S-100 HR (GE Healthcare) column pre-equilibrated with the
same buffer. Fractions of 2 ml were collected at a flow rate of
0.2 ml/min. Samples pooled from different peaks were verified by
SDS-PAGE. The fractions corresponding to EcTI-trypsin complex
were selected and concentrated to around 10 mg/ml. The freshly
prepared complex sample was aliquoted and immediately used for
crystallization trials. The remaining aliquots were stored at280uC
for future optimization.
Amino Acid Sequence of the Isoform of EcTI
Fitting of the published amino acid sequence of EcTI [13] to the
electron density maps (see below) indicated disagreement between
the identity of a number of amino acids and the shape of the
corresponding density, necessitating reassessment of the primary
structure of this protein. Molecular masses of the native and
reduced EcTI were evaluated with the Agilent 1100 electrospray
liquid chromatograph/mass spectrometer. The molecular mass of
the reduced heavy (N-terminal) chain of EcTI was 15418.5 Da,
and for the light (C-terminal) chain 4440.23 Da. Neither of these
masses agreed with the previously published sequence [13] which
was determined by traditional Edman degradation [15], probably
due to the fact of isoforms are frequently found in plant serine
protease inhibitors [26]. Further sequencing was performed after
tryptic digestion of the protein, followed by MS/MS mass
spectrometry and Edman sequencing of the resulting peptides.
Enzyme Inhibition Assay
Inhibition assays with EcTI and STI were performed for a
number of different enzymes. The proteases were pre-incubated
for 15 min at 37uC with the inhibitors, and after that, their
respective substrates were added. The assay conditions were as
follows: Bovine trypsin: 7.0 nM enzyme in 0.05 M Tris/HCl,
pH 8.0, 0.02% CaCl2, 1.0 mM BAPA; Bovine chymotrypsin:
76 nM enzyme in 0.1 M Tris/HCl, pH 8.0, 0.02% CaCl2;
2.0 mM Suc-Phe-pNan; Human plasma kallikrein: 67 nM enzyme
in 0.05 M Tris/HCl, pH 8.0, 0.5 mM H-D-Pro-Phe-Arg-pNan;
Human factor Xa: 56 nM enzyme in Tris/HCl 0.05 M, pH 8.0,
1.5 mM Boc-Ile-Glu-Gly-Arg-AMC; Human factor XIIa: 70 nM
enzyme in Tris/HCl 0.05 M, pH 8.0, 1.5 mM H-D-Pro-Phe-Arg-
pNan; and Human plasmin 3.5 nM enzyme in 0.1 M Tris/HCl,
0.2 M NaCl, pH 7.4, 1.0 mM H-D-Val-Leu-Lys-pNan. The
Kiapp values were determined by adjusting the experimental
points to the equation for tight binding, using a nonlinear
regression with the Grafit program [27].
Protein Crystallization
Initial crystallization trials of the uncomplexed EcTI were
performed by using a Phoenix robot (Art Robbins Instruments,
Mountain View, CA). Several hits were obtained from two
different crystallization screens [JCSG Core II (Qiagen, Valencia,
CA) and Crystal Screen HT (Hampton Research, Aliso Viejo,
CA)]. All these hits, however, were thin needles or needle clusters,
requiring extensive optimization efforts in order to improve the
crystals. Eventually, diffraction quality needle-shaped crystals were
yielded from condition 0.1 M MES pH 5.5, 10% MPD. Crystals
Table 2. Interactions between EcTI and trypsin.
EcTI Trypsin Water Distance(A˚)
Arg12-NH1 Wat90 2.51
His40-O Wat90 2.85
Asn13-O Wat68 2.74
Tyr151-OH Wat68 2.46
Gly14-O Wat16 2.71
Gly148-N Wat16 3.10
Thr61-O Wat143 2.71
Gln192-NE2 Wat143 3.0
Pro62-O Wat21 3.16
Gly219-O Wat21 2.99
Gly216-O Wat21 3.05
Arg64-O Gly193-N 2.82
O Ser195-N 2.96
N Ser214-O 3.11
N Ser195-OG 2.86
NH1 Ser190-OG 2.85
NH2 Asp189-OD2 2.99
NH2 Gly219-O 2.64
NE Wat21 2.69
Gly219-O Wat21 2.99
Gly216-O Wat21 3.05
Ala66-O Wat68 2.95
Tyr151-OH Wat68 2.46
Ala66-N Phe41-O 3.02
Arg92-NH1 Gln221-OE1 2.43
doi:10.1371/journal.pone.0062252.t002
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appeared in several days at 20uC and grew in two weeks to a final
size. For crystallization of EcTI-trypsin complex, a Phoenix robot
was also used to perform the initial trials. The selected initial
crystallization screens include Crystal Screen HT, JCSG II&IV,
Precipitant Synergy (Emerald Biosystems, Bedford, MA), and
Protein Complex Suite (Qiagen, Valencia, CA). The best hit was
obtained from the Protein Complex Suite condition A7 (0.1 M
ammonium sulfate, 0.1 M Tris pH 7.5, 20% PEG1500). After
extensive optimization efforts, diffraction quality crystals were
obtained from 0.1 M ammonium sulfate, 0.1 M Tris pH7.5, 30%
PEG1500, also containing 0.1–0.4 M LiCl or 0.1–0.2 M Li2SO4.
The crystals were also grown at 20uC.
X-ray Data Collection and Processing
Diffraction data were collected at the Southeast Regional
Collaborative Access Team (SER-CAT) beamline 22-ID at the
Advanced Photon Source, Argonne National Laboratory. Single
crystals were transferred to a cryoprotectant solution (mother
liquor with extra 20% glycerol) for approximately 2 min and then
were flash frozen at 100 K in a stream of liquid nitrogen. Crystals
of the unbound EcTI diffracted X-rays to the resolution of 1.75 A˚.
Diffraction data were indexed, integrated, and scaled with the
program XDS [28]. The crystal belongs to the space group C2
with unit cell parameters a = 160.7 A˚, b = 34.9 A˚, c = 65.5 A˚,
b=107.7u. The asymmetric unit contains two molecules of EcTI.
The estimated Matthews coefficient is 2.23 A˚3Da21, correspond-
ing to 45% solvent content. A crystal of the complex of EcTI with
trypsin diffracted X-rays to the resolution of 2.0 A˚ and data were
Figure 8. Structural basis for the differences in the inhibitory properties of Kunitz inhibitors towards different serine proteases. (a)
Two possible areas of conflict between EcTI and Factor Xa. Factor Xa (gray) is superimposed on trypsin (green) complexed with EcTI (yellow).
Complexes of STI and TKI are superimposed on the basis of their trypsin components (orange and magenta, respectively). (b) The third possible area
of conflict between EcTI and Factor Xa. A modeled surface of Factor Xa (PDB ID: 2JKH) is gray. The colors for other molecules are as in (a). (c) Different
orientation of the N terminus in EcTI (yellow) compared to STI (magenta) and TKI (orange).
doi:10.1371/journal.pone.0062252.g008
Table 3. Data collection and structure refinement.
Data collection
EcTI-trypsin complex EcTI unbound
Space group C2 C2
Molecules/a.u. 2 (1 complex) 2
Unit cell a, b, c (A˚); b (u) 73.3, 38.6, 122.8, 104.2 160.7, 34.9, 65.5, 107.7
Resolution (A˚)* 20–2.0 (2.2–2.0) 20.0–1.75 (2.0–1.75)
Rmerge
{ (%) 8.1 (39.6) 7.8 (34.6)
No. of reflections (measured/unique) 55,037/21,100 109,420/34,536
,I/sI. 8.63 (1.72) 10.75 (2.91)
Completeness (%) 92.1 (80.9) 97.3 (94.1)
Redundancy 2.6 (1.89) 3.2 (2.6)
Refinement
Resolution (A˚) 20.0–2.0 20–1.75
No. of reflections (refinement/Rfree) 21,100/844 34,535/1037
R/Rfree
` 0.196/0.258 0.183/0.237
No. atoms
Protein 2936 2680
Ligands 5 22
Water 148 229
B-factors (A˚2)
Protein 36.55 28.79
Reactive loop 30.91 23.56
Ligands/water 34.51 37.78
R.m.s. deviations from ideal
Bond lengths (A˚) 0.008 0.009
Bond angles (u) 1.185 1.310
PDB accession code 4J2Y 4J2K
*The highest resolution shell is shown in parentheses.
{Rmerge =ghgi|Ii–ÆIæ|/ghgiIi, where Ii is the observed intensity of the i-th measurement of reflection h, and ÆIæ is the average intensity of that reflection obtained from
multiple observations.
`R=g||Fo|–|Fc||/g|Fo|, where Fo and Fc are the observed and calculated structure factors, respectively, calculated for all data. Rfree was defined in [33].
doi:10.1371/journal.pone.0062252.t003
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also processed with the program XDS. The crystal also belongs to
the space group C2 but with different unit cell parameters,
a = 73.3 A˚, b = 38.6 A˚, c = 122.8 A˚, b=104.2u. Each asymmetric
unit contains a single complex. The estimated Matthews
coefficient is 1.74 A˚3Da21, corresponding to 29.3% solvent
content. Data processing statistics for both crystal forms are
shown in Table 3.
Structure Determination and Refinement
The structure of the complex of EcTI and bovine trypsin was
solved by molecular replacement with the program Phaser
[29,30]. Soybean trypsin inhibitor structure (PDB ID: 1AVW)
and bovine pancreatic trypsin structure (PDB ID: 2BZA) were
used as starting models. A unique solution representing a single
complex in an asymmetric unit was found with data between 20
and 3 A˚, with a Log-Likelihood gain of 849.7. The resulting
electron density map was fully interpretable, verifying the
correctness of the solution and indicating that the identity of
several amino acids in the inhibitor needed to be changed. Further
refinement was performed with REFMAC5 [31] and PHENIX
[32], using all data between 20 and 2.0 A˚, after setting aside 4% of
randomly selected reflections (844 total) for calculation of Rfree
[33]. Isotropic individual B-factors were refined, with the TLS
parameters added in the final stages of refinement. After several
further rounds of automated refinement and manual correction
using COOT [34], the structural model was finally refined to an
R-factor of 19.6% and Rfree of 25.8%. The structure of free EcTI
was determined by molecular replacement with PHASER [30]
using the coordinates of EcTI part of EcTI-trypsin complex as a
starting model. Refinement was carried out using a protocol
similar to the one reported above for EcTI-trypsin complex. 3%
randomly selected reflections (1037 total) were set aside for
calculation of Rfree. The final model was refined to 1.75 A˚
resolution, resulting in an R-factor of 18.3% and Rfree of 23.7%
(Table 3). The structures were compared using the DALI server
[35] with the set of Protein Data Bank structures with less than
90% sequence identity.
Accession Numbers
Atomic coordinates and structure factors of the refined models
of free EcTI and of its complex with trypsin were deposited in the
PDB with accession codes 4J2K and 4J2Y, respectively.
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